Arbutus Biopharma Corporation (ABUS) Stock
Fundamentals
Recent news

ABUS Stock Surges 10% Today — What’s Driving This Super Rally?
ABUS Stock Surges 10% Today — What’s Driving This Super Rally?
ABUS

ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection?
ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection?
ABUS

Moderna-Arbutus-Genevant Patent Settlement: Wall Street Says Not Best-Case Scenario But Removes Overhang For MRNA Stock
Moderna-Arbutus-Genevant Patent Settlement: Wall Street Says Not Best-Case Scenario But Removes Overhang For MRNA Stock
ABUS

MRNA Shares Rally After Hours On Inking Settlement Deal Over Vaccine Patent Row
MRNA Shares Rally After Hours On Inking Settlement Deal Over Vaccine Patent Row
ABUS
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.06 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

ABUS Stock Surges 10% Today — What’s Driving This Super Rally?
ABUS Stock Surges 10% Today — What’s Driving This Super Rally?
ABUS

ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection?
ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection?
ABUS

Moderna-Arbutus-Genevant Patent Settlement: Wall Street Says Not Best-Case Scenario But Removes Overhang For MRNA Stock
Moderna-Arbutus-Genevant Patent Settlement: Wall Street Says Not Best-Case Scenario But Removes Overhang For MRNA Stock
ABUS

MRNA Shares Rally After Hours On Inking Settlement Deal Over Vaccine Patent Row
MRNA Shares Rally After Hours On Inking Settlement Deal Over Vaccine Patent Row
ABUS

Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute
Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute
ABUS

ABUS Stock On Track For Biggest Intraday Drop In Over 5 Years – What’s The Issue Around Its Patent In Europe?
ABUS Stock On Track For Biggest Intraday Drop In Over 5 Years – What’s The Issue Around Its Patent In Europe?
ABUS

Arbutus (ABUS) Upgraded to Buy: Here's What You Should Know
Arbutus (ABUS) Upgraded to Buy: Here's What You Should Know
ABUS

Biopharmaceutical Stocks: The Bottoming Process Is Playing Out
Biopharmaceutical Stocks: The Bottoming Process Is Playing Out
ABUS

Arbutus, Genevant sue Moderna, citing patent infringement
Arbutus, Genevant sue Moderna, citing patent infringement
ABUS

Arbutus files patent infringement lawsuit against Moderna
Arbutus files patent infringement lawsuit against Moderna
ABUS
About Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Lindsay Androski J.D., M.B.A. | President, CEO & Chairman | 1977 |
| Mr. Tuan Nguyen | Chief Financial Officer | 1976 |
| Mr. Andrew J. Sung | General Counsel | — |
| Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C. | Corporate Secretary | 1951 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
0 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +0.5 | -5.8 | -18.4 | -15.6 | ||||||||
| 2022 | -29.4 | +9.6 | -3.9 | -24.4 | -0.4 | +10.2 | -17.5 | +0.9 | -16.6 | +20.6 | -2.9 | +0.0 |
| 2023 | +35.0 | -4.1 | +7.8 | -18.0 | -1.2 | -8.0 | -4.4 | -6.9 | -1.0 | -4.7 | +11.4 | +23.2 |
| 2024 | -8.5 | +16.7 | -7.5 | +6.6 | +24.9 | -9.6 | +20.8 | +1.6 | -3.5 | +0.5 | -12.6 | -5.5 |
| 2025 | +1.2 | +5.2 | +2.0 | +2.0 | -6.9 | -8.0 | +3.1 | +13.5 | +18.8 | +3.1 | -3.7 | +14.3 |
| 2026 | -13.4 | +6.2 | -3.6 | -7.1 | +5.6 | +7.1 | -8.2 | +16.5 | -4.7 |



